Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

AZN AstraZeneca PLC

78,35

-0,07 (-0,09%)

Vor Marktöffnung

Zuletzt aktualisiert: 14:21:11

Verzögert um 15 Minuten

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more AstraZeneca Charts.

AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more AstraZeneca Charts.

News AstraZeneca PLC

IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
Montag 17 Juni 2024 (3 Tage vor) • Business Wire

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
Sonntag 16 Juni 2024 (4 Tage vor) • Business Wire

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
Mittwoch 12 Juni 2024 (1 Woche vor) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 12 Juni 2024 (1 Woche vor) • Edgar (US Regulatory)

TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Montag 10 Juni 2024 (1 Woche vor) • Business Wire

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
Donnerstag 6 Juni 2024 (2 Wochen vor) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 4 Juni 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Dienstag 4 Juni 2024 (2 Wochen vor) • Edgar (US Regulatory)

Economic Worries May Lead To Weakness On Wall Street
Dienstag 4 Juni 2024 (2 Wochen vor) • IH Market News

AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
Dienstag 4 Juni 2024 (2 Wochen vor) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 3 Juni 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 3 Juni 2024 (2 Wochen vor) • Edgar (US Regulatory)

Weitere AstraZeneca PLC News-Artikel

Coolabah Metals

Amundi Index Solutions

San Ju San Financial (PK)

NLBNPIT20G20 20240920 0....

Reit Growth & Income Sel...

Alan Allman Associates

Temple Quy.85 D

Hanetf ETC Group Group W...

NLBNPIT20458 20991231 56...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen